Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 64

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 64
---
483, asserting that we are in violation of the law; |

| ● | request voluntary product 
 recalls;                  |

| ● | seek an injunction or impose                                    
 administrative, civil, or criminal penalties or monetary fines; |

| ● | suspend or withdraw regulatory 
 approval;                      |

| ● | suspend any ongoing clinical 
 trials;                      |

| ● | refuse to approve a pending                                                   
 BLA or comparable foreign marketing application (or any supplements thereto); |

| ● | restrict the marketing           
 or manufacturing of the product; |

| ● | seize or detain the product                                         
 or otherwise require the withdrawal of the product from the market; |

| ● | refuse to permit the import         
 or export of product candidates; or |

| ● | refuse to allow us to enter                            
 into supply contracts, including government contracts. |

Any government investigation
of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
The occurrence of any event or penalty described above may inhibit our ability to commercialize CER-1236 or other product candidates
and adversely affect our business, financial condition, results of operations, and prospects.

Prior treatments can alter the cancer or target of CER-T cell therapy and negatively impact chances for achieving clinical activity with our programmed T cells.

Patients with hematological
cancers receive highly toxic lympho-depleting chemotherapy as their initial treatment. These therapies can impact the viability of the
T cells collected from the patient and can contribute to highly variable responses to programmed T cell therapies. Patients could also
have received prior therapies that target the same target antigen on the cancer cells as our intended programmed T cell product candidate
and thereby lead to a selection of cancer cells with low or no expression of the target. Cancers also naturally evolve and select clones
with low or no expression of the target. As a result, our programmed T cell product candidates may not recognize the cancer cell and
may fail to achieve clinical activity. If any of our product candidates do not achieve a sufficient level of clinical activity, we may
discontinue the development of that product candidate, which could adversely affect our business, financial condition, results of operations,
and prospects.

<div align='center'>31</div>

Risks Related to Reliance on Third-Parties

We will rely on third parties to conduct our clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product